Zina Chatzidimitriadou

ZINA CHATZIDIMITRIADOU represents life sciences and medtech clients on all aspects of product lifecycle management under UK and EU law. A former scientist, having worked in molecular biology research, Zina brings with her the ability to effectively understand the science. She has a particular focus on advising and speaking on regulatory protections and IP rights, cell and gene therapies, market access, digital health, and artificial intelligence.

Zina’s practice covers the pharmaceutical, medical device, medtech, biotechnology, food, cosmetics, and novel products (such as cannabidiol or CBD) industries on both advisory and contentious matters. Zina also co-leads the industry benchmarking group, ctlegal, for clinical trials in the pharmaceutical industry.

• Digital health and AI: Zina is particularly active in matters of digital health and advises extensively on the development and use of wearables, novel clinical study designs, telehealth services, and pharma-medtech partnerships, as well as on the compliance with the applicable medical device and in vitro diagnostic frameworks. She has a keen interest in the interplay with the evolving artificial intelligence landscape.
• Market access: One key area of Zina’s practice is on drug pricing and reimbursement and designing market access strategies for novel products including cell and gene therapies, both at national and EU level, enabling early engagement with key stakeholders, coordinating with other jurisdictions, and appearing before payers and national agencies.
• EU/UK pharma and IP law: Zina advises companies on the protection and enforcement of their IP regulatory rights, including orphan market exclusivity, regulatory data protection, pediatric rewards, data transparency, and product liability. In addition, she provides assistance on compliance with industry and regulatory practice codes and advertising and promotion practices. She has successfully represented clients before the Committee for Orphan Medicinal Products (COMP) and the Paediatric Committee (PDCO) of the European Medicines Agency, as well as the UK National Institute for Health and Care Excellence for pricing and reimbursement matters. She frequently counsels on promotion and advertising matters, interactions with healthcare professionals, transparency obligations, and strategic protection from compounding practices. 
• Advanced therapies: Zina is particularly keen to assist novel products, such as ATMPs, to be developed and provided to patients. This is particularly so through new approaches to approval and market access, but also thought leadership on pathways including real world data/evidence (RWD/RWE).

Zina’s litigation experience includes representing clients before European bodies such as the European Commission and the European Medicines Agency, EU and national courts, tribunals, and professional bodies and committees.

Zina has received acknowledgement from industry ranking guides:

• Legal 500 UK 2026 - Named as "Leading Associate." Sources comment: "Zina's in-depth knowledge is peerless and has the ability to horizon scan the political space to consider how the geopolitical space will affect the commercial/regulatory position of the client.”, and "Zina Chatzidimitriadou is praised for her ’in-depth knowledge’ across all aspects of product lifecycle management in the UK and EU."
• Legal 500 UK 2025 – Named as “Leading Associate.”
• Legal 500 UK 2024 – Named as “Rising Star” for Life Sciences and Healthcare, where clients comment: “Zina Chatzidimitriadou provides practical, pragmatic, and commercially aware legal advice, always listening to the client. She is approachable and reactive which demonstrates fantastic customer care.”

She has also been named by Law.com International 2025 as one of the “Rising Stars: UK Legal Industry’s Best Up-And-Coming Women.”

Zina received the award of the “EU Regulatory Rising Star” at the LMG Life Sciences Awards EMEA 2025.

Zina’s representative matters include advising:

• A major global biopharma company on the use and incorporation of genomic sequencing companion diagnostics into its pharmaceutical product development and commercialization.
• A U.S. biotechnology company, which develops a number of cell and gene therapies, on the strategy and development of its market access plans.
• A British digital healthtech company with all aspects of compliance, partnerships with pharma counterparts, and regulatory considerations for its pipeline products.
• A publicly listed global pharmaceutical company on its successful appeal to the Committee on Orphan Medicinal Products of the EMA regarding the orphan status of its product. 
• A major global biomedical testing company on compliance with the Medical Device and In Vitro Diagnostic Regulation and on advertising and promotional strategies.
• An international digital health company on its clinical study plans, certification procedure and dialogue with Notified Body, post-market compliance obligations, and various commercial considerations.
• KKR on its majority acquisition of Biosynth Carbosynth, a Swiss life sciences reagents and custom synthesis and manufacturing services company.
• CA Healthcare Acquisition Corp., a SPAC focused on investing in a growth-oriented healthcare company, in its approximately US$3 billion business combination with LumiraDx Limited, a next-generation point of care diagnostics testing company.
• Bain Capital on its acquisition of Astral SteriTech Private Limited, a leading pharmaceutical manufacturer.
• Great Hill Partners in connection with its acquisition of Notonthehighstreet, a UK curated online marketplace.
• H.I.G. Capital and Vernacare on the acquisition of Infection Prevention.
• Goldman Sachs Private Capital on its investment in DocPlanner Group, a healthcare booking platform provider with operations in 15 countries.

 

• Member of the Drug Information Association (DIA)
• Member of IPSoc, the society for junior IP practitioners
• Member of ChIPS (Chiefs in Intellectual Property), a non-profit organization focused on advancing and connecting women in technology, law, and policy

A keen advocate, Zina participates in a wide range of pro bono initiatives of the firm, including assisting with PIP cases at the Horizon Legal Advice Clinic, the Not Beyond Redemption initiative, helping children and young people protect their immigration rights, and advising emerging enterprises on a number of commercial issues.